Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 145,407 matching trials from the live ClinicalTrials.gov search.
Conditions
Parkinson Disease, Multiple Sclerosis, Stroke
Interventions
Low-Fidelity PDS, High Fidelity Fixed-Base Simulator
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
25 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Systemic Lupus Erythematosus
Interventions
Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 10 more
Conditions
Type 2 Diabetes
Interventions
Muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
70
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mesa, Arizona + 67 more
Conditions
Heart Failure, Pulmonary Hypertension
Interventions
Sildenafil, Placebo oral capsule
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Hartford, Connecticut
Conditions
Attention Deficit Disorders With Hyperactivity
Interventions
Pharmacogenomics report
Diagnostic Test
Lead sponsor
Clinical and Translational Genome Research Institute, Inc.
Other
Eligibility
6 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Hamilton, New Jersey • Mountainside, New Jersey • Toms River, New Jersey
Conditions
Depression, Anxiety
Interventions
Wysa, Harvard College App
Other
Lead sponsor
Harvard University
Other
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Breast Cancer, Preneoplastic Conditions, Ductal Carcinoma in Situ
Interventions
Nipple aspirator, Ductal lavage microcatheter, Blood draw
Device
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Santa Monica, California
Completed Not applicable Interventional Accepts healthy volunteers

Written Exposure Therapy for Posttraumatic Stress Disorder

NCT01800773
Conditions
Posttraumatic Stress Disorder
Interventions
Written Exposure Therapy, Cognitive Processing Therapy
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chest Pain, Shortness of Breath
Interventions
Echocardiogram
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Prostate Cancer
Interventions
Abiraterone, Leuprolide, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Houston, Texas • Seattle, Washington + 1 more
Conditions
Head Injury, Concussion, Brain Injuries, Traumatic Brain Injury
Interventions
No intervention applied - observational study only
Other
Lead sponsor
Federation Internationale de Football Association
Other
Eligibility
Male only
Enrollment
832 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Major Depressive Disorder, Depression, Healthy
Interventions
SP-624, Placebo
Drug
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Garden Grove, California • Lincoln, Nebraska
Terminated Phase 4 Interventional Results available

Pancreatic Enzyme Supplementation for Celiac Disease

NCT02475369
Conditions
Celiac Disease
Interventions
pancrelipase
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Depression, Caregivers, Dementia
Interventions
WeACT
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
22
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 19 more
Conditions
Lung Cancer
Interventions
SBRT 40.0 Gy, SBRT 42.5 Gy, SBRT 45.0 Gy, SBRT 47.5 Gy, SBRT 50.0 Gy, SBRT 52.5 Gy, SBRT 55.0 Gy, SBRT 57.5 Gy, SBRT 60.0 Gy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
57
States / cities
Peoria, Arizona • Scottsdale, Arizona • Burbank, California + 50 more
Completed Phase 2Phase 3 Interventional Results available

Voucher-Based Incentives in a Prevention Setting

NCT00607269
Conditions
Substance-related Disorders
Interventions
Voucher-Based Reinforcement Therapy
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Neoplasm, Refractory Childhood Malignant Neoplasm
Interventions
Functional Precision Medicine
Device
Lead sponsor
Florida International University
Other
Eligibility
1 Day to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 4 Interventional Accepts healthy volunteers

Abilify Therapy for Reducing Comorbid Substance Abuse

NCT00208169
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse
Interventions
Aripiprazole
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Alcohol Abuse
Interventions
Enhanced Motivational Interview, Standard Motivational Interview or viewing DVD
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Hypogonadism
Interventions
dutasteride, placebo
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Completed Phase 2 Interventional Results available

Dose-Ranging Study of the Bimatoprost Ocular Insert

NCT02358369
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost, Timolol 0.5%, Placebo Ocular Insert, Placebo Eye Drops
Drug · Device
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
10
States / cities
Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 7 more
Active, not recruiting Early Phase 1 Interventional

Tolerance Through Mixed Chimerism (Sip-Tego)

NCT06972069
Conditions
Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion, Immunosuppression After Kidney Transplantation
Interventions
Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)
Procedure · Drug
Lead sponsor
Tatsuo Kawai, MD, PhD
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts